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Neurogenic orthostatic hypotension (nOH) refers to
decreased blood pressure (BP) during head-up posture
change (ie, standing or head-up tilt) resulting from auto-
nomic failure. Failure of the sympathetic baroreflex results
in inadequate norepinephrine release from sympathetic
nerves innervating the blood vessels and heart.1 Autonomic
failure occurs in several central and peripheral neurologic
disorders, including Parkinson disease (PD), multiple sys-
tem atrophy (MSA), pure autonomic failure, and peripheral
autonomic neuropathy.1,2 Estimates suggest that nOH is
present in 37% to 58% of patients with PD, 75% of patients
with MSA, and 100% of patients with pure autonomic fail-
ure.3 Orthostatic hypotension is associated with significant
morbidity and mortality4; patients with nOH have an
increased risk of cardiovascular complications as well
(eg, heart failure, atrial fibrillation), and many have coexist-
ing cardiovascular comorbidities (eg, hypertension, cardiac,
or cerebrovascular conditions).4,5American Society of Hypertension. This is an open access article
by-nc-nd/4.0/).
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the United States for the treatment of symptomatic nOH in
patients with primary autonomic failure (PD, MSA, pure
autonomic failure), dopamine b-hydroxylase deficiency,
or nondiabetic autonomic neuropathy (NDAN).6 In short-
term phase 3 trials, droxidopa significantly improved the
hallmark symptoms of nOH (eg, orthostatic dizziness,
lightheadedness, or the ‘‘feeling like you are about to black
out’’), with patients reporting improved symptom severity
and impact on daily activities compared with placebo.7–9
Droxidopa also increased standing systolic BP (SBP) in
these patients.9,10 Short-term treatment with droxidopa
was well tolerated in these studies, and most adverse events
(AEs) were mild or moderate in severity.7–9 The incidence
of supine hypertension, defined as SBP >180 mm Hg,
ranged from 5% to 14%. Rates of other cardiovascular
events were low (eg, coronary artery disease, hypertension
[0%–8%]).
Previous trials evaluated the efficacy and safety of drox-
idopa over relatively short treatment durations of 1–2 and
8–10 weeks.7–9 The objective of the present study was to
evaluate the long-term safety of droxidopa for the treatment
of symptomatic nOH based on frequency and type of AEs,
BP and heart rate, and laboratory findings.
Methods
This was a phase 3, multinational, multicenter, open-
label study in ambulatory patients with symptomatic nOH
that assessed the long-term safety of droxidopa
(ClinicalTrials.gov identifier, NCT01132326). Patients
entering this long-term study were required to have
participated in a prior short-term,9 8- to 10-week,8,10 or
1-year11,12 double-blind, placebo-controlled droxidopa
trial. This long-term, open-label study was conducted be-
tween February 2009 and October 2012.PatientsEligible patients were 18 years of age with symptom-
atic nOH (defined as a 20-mm Hg reduction in SBP on
standing) associated with PD, MSA, pure autonomic fail-
ure, or NDAN. Key exclusion criteria included use of vaso-
constricting agents or long-acting antihypertensive
medications, uncontrolled cardiac arrhythmias, a history
of myocardial infarction within the past 2 years, current un-
stable angina, uncompensated congestive heart failure
(New York Heart Association Class III or IV), or diabetic
autonomic neuropathy. Patients with sustained severe hy-
pertension (defined as SBP 180 mm Hg or diastolic BP
[DBP] 110 mm Hg) were also excluded. To assess for
the presence of severe hypertension, BP was measured in
a supine (ie, semirecumbent; head and torso elevated
approximately 30-degrees from horizontal) or seated posi-
tion at three consecutive measurements within 1 hour.TreatmentsDroxidopa was administered at doses of 100 to 600 mg
in 100-mg increments taken three times daily (TID); doses
were taken upon waking and at approximately 4-hour inter-
vals to allow the last dose to be taken in the late afternoon
and early enough before bedtime to minimize the risk of
hypertension during sleep (ie, supine hypertension). Pa-
tients received individualized doses that had been identified
during the titration period of a previous study, with some
exceptions: all patients who entered the present study
from the 8- to 10-week double-blind study underwent
dose titration in the present study. At the discretion of
the treating investigator physician, droxidopa doses could
be adjusted up or down in single steps for efficacy or
safety. Dose escalation was stopped if the patient had sus-
tained SBP >180 mm Hg or DBP >110 mm Hg in the su-
pine (or semirecumbent) position was unable to tolerate
side effects believed to be related to the study drug or
reached the maximum dose of droxidopa (600 mg TID;
1800 mg/d).
Scheduled assessments were conducted at months 1 and
3, and every 3 months thereafter. Vasoconstricting agents
(eg, ephedrine, dihydroergotamine, midodrine), tryptamine-
based drugs (triptans; eg, sumatriptan), cyclopropane or
halogen-containing inhalational anesthetics (eg, halothane),
catecholamine-containing preparations (eg, isoproterenol
[isoprenaline]), nonselective monoamine oxidase inhibi-
tors, long-acting antihypertensives, and ergotamine deriva-
tives (except medications for PD) were prohibited during
the study. Fludrocortisone was permitted, as were all PD
drugs.AssessmentsAEs, vital signs, and laboratory testing results were re-
corded at each clinic visit. Investigators classified AEs by
severity after obtaining the patient’s medical history. Labo-
ratory testing included hematology, chemistry, and urinaly-
sis; women of childbearing potential underwent a
pregnancy test at each study visit. Vital sign assessment
included BP (measured using the same calibrated equip-
ment at each visit), heart rate, temperature, and weight.Data AnalysesAll patients who received at least 1 dose of droxidopa
were evaluated for safety. Continuous variables were sum-
marized descriptively; frequencies and percentages were
calculated for categorical variables. In comparisons with
baseline, baseline values reflect evaluations performed
before the first dose of study treatment in a short-term, dou-
ble-blind study unless the last visit in these studies occurred
>1 month before the start of the present study; all patients
were off study drug at the time of baseline evaluations.
Table 2
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Selected concomitant medication use* (safety population,
N ¼ 350)Patients and Treatment
Anatomical Therapeutic Chemical Class n (%)
Dopa and dopa derivativesy 234 (66.9)
Mineralocorticoidsz 118 (33.7)
Monoamine oxidase B inhibitors 87 (24.9)
Dopamine agonists 78 (22.3)
Beta blocking agents, selective 14 (4.0)
Angiotensin-converting enzyme inhibitors, plain 10 (2.9)
Dihydropyridine derivatives 9 (2.6)
Imidazoline receptor agonists 9 (2.6)
Organic nitrates 7 (2.0)
Beta blocking agentsx 5 (1.4)
Alpha and beta blocking agents 3 (0.9)
Thiazides, plain 3 (0.9)
Angiotensin II antagonists, plain 1 (0.3)
Beta blocking agents, nonselective 1 (0.3)
Beta blocking agents (selective) and thiazides 1 (0.3)A total of 350 patients, enrolled at 111 centers in 7 coun-
tries, were included in the safety analysis. The mean age
was 66 years, and most patients were men and white
(Table 1). Levodopa and dopa decarboxylase inhibitors
(carbidopa or benserazide combinations), with or without
catechol-O-methyl transferase inhibitors (entacapone),
were used by 66.9% of patients (n ¼ 234/350; Table 2).
Monoamine oxidase B inhibitors or dopamine agonists
were used by 24.9% (n ¼ 87/350) and 22.3% (n ¼ 78/
350) of patients, respectively. Fludrocortisone or fludrocor-
tisone acetate was used by 33.7% patients. Short-acting an-
tihypertensives of various drug classes were used by 0.3%–
4.0% of the study population. The most common reason for
noncompletion of the study (36.7% of the total population)
was the transition of patients to a compassionate-use accessTable 1
Demographics and baseline* characteristics (safety population,
N ¼ 350)
n (%)
Age, y
Mean (SD) 65.9 (15.16)
Range 18–90
Sex, n (%)
Male 214 (61.1)
Female 136 (38.9)
Race/ethnicity, n (%)
White 337 (96.3)
Hispanic/Latino 7 (2.0)
Black/African American 4 (1.1)
Asian 2 (0.6)
Primary clinical diagnosis, n (%)
Parkinson disease 232 (66.3)
Pure autonomic failure 68 (19.4)
Multiple system atrophy 33 (9.4)
Nondiabetic autonomic
neuropathy
8 (2.3)
Other 7 (2.0)
Missing 2 (0.6)
Seated systolic blood pressure, mm Hg
Mean (SD) 121.97 (23.49)
Range 56–208
Seated diastolic blood pressure, mm Hg
Mean (SD) 72.47 (11.98)
Range 40–111
Heart rate, bpm
Mean (SD) 71.33 (10.10)
Range 41–109
SD, standard deviation.
* Long-term, open-label study baseline values reflect evalua-
tions performed before the first dose of study treatment in a
short-term, double-blind study unless the last visit in these studies
occurred >1 month before the start of the present study; all pa-
tients were off study drug at the time of baseline evaluations.
* Concomitant medications include all medications taken during
the study, including those started before but ongoing at first dose. If
a patient had multiple occurrences of a medication, the patient is
presented only once in the respective patient count. Medications
are coded using the World Health Organization Drug dictionary.
y Includes levodopa and dopa decarboxylase inhibitors (carbi-
dopa or benserazide combinations), with or without catechol-O-
methyl transferase inhibitors (entacapone).
z Fludrocortisone or fludrocortisone acetate.
xRoute of administration not specified.program; this program was available to patients at non-US
sites after the study was terminated in the European Union
and Canada. Other reasons for study discontinuation
included withdrawal of consent (18.8%), AEs (17.0%),
and lack of efficacy (11.5%; Figure 1).
The mean duration of exposure to droxidopa during the
study was 362.6 days (median, 265 days; range, 2 to
1133 days). The mean prescribed daily dose was
419.8 mg TID (median, 409.1 mg TID). The most
commonly administered dose of droxidopa was 600 mg
TID (42.3%, n ¼ 148/350), while 14.3%, 16.9%, and
15.7% of patients received 300, 400, or 500 mg TID,
respectively.SafetyAEs were reported by 75.1% of patients (n ¼ 263/350;
Table 3). The most frequently reported AEs were falls
(23.4%), urinary tract infection (13.4%), headache
(12.0%), syncope (12.0%), and dizziness (9.7%). The ma-
jority (92.3%) of AEs were mild or moderate in severity,
and most of the common AEs (ie, falls, urinary tract infec-
tion, and syncope) were reported by investigator physicians
to be manifestations of the underlying diseases (nOH, PD,
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Figure 1. Reasons for not completing study per protocol: aPatients discontinued the current long-term, open-label study when the study
was transitioned to a compassionate-use access program in the European Union and Canada. bPatient withdrew consent, n ¼ 40; care-
giver withdrew consent, n ¼ 1. cProtocol violation, declining health, and pregnancy (n ¼ 1 each).
Table 4
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AEs (66.9%; n ¼ 234/263) resolved and required no change
to dose of study drug (77.1%, n ¼ 249/263). Dosing
changes because of an AE included dose decrease for
9.4% of patients (n ¼ 33/263) and dose interruption (but
not discontinuation) for 10.3% of patients (n ¼ 36/263).
AEs leading to discontinuation of study drug were reportedTable 3
Most commonly reported (5% of patients) adverse events (safety
population, N ¼ 350)
Preferred Term* n (%)
Fall 82 (23.4)
Gastrointestinal disorders 77 (22.0)
Urinary tract infection 47 (13.4)
Headache 42 (12.0)
Syncope 42 (12.0)
Dizziness 34 (9.7)
Fatigue 28 (8.0)
Nausea 23 (6.6)
Asthenia 23 (6.6)
Back pain 20 (5.7)
Contusion 18 (5.1)
*Medical Dictionary for Regulatory Activities, version 10.1.for 13.4% of patients (n ¼ 47/350). There were four discon-
tinuations due to a hypertension-related diagnosis.
Serious AEs (SAEs) were experienced by 23.7% of pa-
tients (n ¼ 83/350; Table 4); most SAEs were judged toSerious adverse events reported by 0.9% of patients (safety
population, N ¼ 350)
Preferred Term* Patients, n (%)
Any serious adverse event 83 (23.7)
Syncope 10 (2.9)
Pneumonia 7 (2.0)
Dehydration 7 (2.0)
Respiratory failure 4 (1.1)
Fall 4 (1.1)
Transient ischemic attack 3 (0.9)
Sepsis 3 (0.9)
Urinary tract infection 3 (0.9)
Hip fracture 3 (0.9)
Skin laceration 3 (0.9)
Orthostatic hypotension 3 (0.9)
Aspiration 3 (0.9)
Pneumonia aspiration 3 (0.9)
Asthenia 3 (0.9)
*Medical Dictionary for Regulatory Activities, version 10.1.
Table 5
Fatal serious adverse events in the study17
Age Sex Primary
Diagnosis
Preferred Term Dose (TID) at
Time of Event, mg
Study Day*/
Duration
Severity
61 M MSA Respiratory failure 600 mg 598/3 Severe
57 M MSA Carotid artery thrombosis 600 mg 146/1 Severe
56 F MSA Circulatory collapse 500 mg 128/1 Moderate
62 M Pure autonomic
failure
Myocardial infarctiony 600 mg 550/1 Severe
53 M MSA MSA 600 mg 777/1 Severe
75 M NDAN Myocardial infarction 400 mg 363/1 Severe
61 F PD Respiratory failure 600 mg 1033/1 Severe
70 F MSA Acute respiratory failure 600 mg 443/5 Severe
73 M MSA Subdural hemorrhage 600 mg NDz/ND Severe
78 M PD Unknown causex 600 mg 439/ND ND
79 M MSA Sepsis 800 mg/dk 453/20 Severe
80 M PD Cardiorespiratory arrest 600 mg 37/2 Severe
79 M PD Pneumonia aspiration 600 mg 735/2 Severe
83 F PD Respiratory failure 400 mg, 100 days before
respiratory failure
189/1 Severe
78 M PD Cardiorespiratory arrest{ 200 mg 104/1 Severe
85 M PD Respiratory arrest 600 mg 549/9 Severe
83 F PD Cardiac arrest 600 mg 530/1 Severe
62 M PD Urosepsisx,# 600 mg 500/1 ND
55 F MSA Brain edema 500 mg 51/5 Severe
60 F MSA Pneumonia 300 mg 169/17 Severe
F, female; M, male; MSA, multiple system atrophy; ND, not determined; NDAN, nondiabetic autonomic neuropathy; PD, Parkinson dis-
ease; TID, 3 times daily.
* Study day equals (day of onset of adverse event minus first day of treatment) plus 1.
y Patient had a history of myocardial infarction/coronary heart disease and angina (all >2 years before study entry).
z Patient took doses of 200 mg, 200 mg, then 400 mg droxidopa daily.
x Patient death noted in study follow-up listing.
k Patient did not have a recorded start date for the adverse event leading to death.
{ Patient had a history of incomplete bundle branch block, paroxysmal atrial fibrillation, and tachycardia.
# Patient experienced a fatal event of urosepsis 23 days after discontinuation of study drug because of a serious adverse event of
dehydration.
759S. Isaacson et al. / Journal of the American Society of Hypertension 10(10) (2016) 755–762be related to the underlying neurogenic diseases. The most
common SAEs were syncope (2.9%), pneumonia (2.0%),
and dehydration (2.0%). The rates of SAEs were highest
in patients with a primary diagnosis of MSA (45.5%)
compared with those with PD (25.0%) or pure autonomic
failure (8.8%). There were 35 discontinuations due to
SAEs.
Nineteen patients (5.4%) reported 25 cardiac-related
AEs; 10 events were mild, 9 were moderate, and 6 were
severe. The severe cardiac-related AEs included atrial
fibrillation (n ¼ 1), cardiorespiratory arrest (n ¼ 2),
myocardial infarction (n ¼ 2), and cardiac arrest (n ¼ 1).
Cardiac-related AEs reported by >1 patient were atrial
fibrillation (5 patients [1.4%]) and atrial flutter, brady-
cardia, cardiorespiratory arrest, myocardial infarction, and
palpitations (2 patients [0.6%] each). Eleven cardiac-
related AEs were considered SAEs. The patient who expe-
rienced atrial flutter had a medical history of atrial
fibrillation.There were 20 deaths during the study (Table 5). Nearly
half of these deaths (n ¼ 9/20; 45.0%) occurred in patients
with a diagnosis of MSA, and 60.0% of deaths (n ¼ 12/20)
were associated with progression of disease, respiratory
failure, or infection. The cause of one death was unknown.
The remaining deaths (n ¼ 7/20; 35.0%) were reported to
have cardiovascular causes. Three patients with fatal car-
diovascular SAEs had a medical history of cardiovascular
conditions. One fatal SAE (myocardial infarction) occurred
in a 62-year-old patient with pure autonomic failure after
approximately 18 months of treatment. This patient had a
history of myocardial infarction, coronary artery disease,
and angina (all >2 years before study entry), and the
SAE was assessed by the investigator as not related to study
drug (Table 5). The duration of exposure to droxidopa in
the present study at the time of the fatal events ranged
from 37 to 777 days (median, 439 days). There was no clus-
tering of fatal events around the initiation of droxidopa.
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related to droxidopa.Vital Signs
Blood Pressure
SBP and DBP were recorded at each study visit in the
seated or supine (ie, semirecumbent) position. At baseline,
the mean (SD) SBP was 122 (23.5) mm Hg and the mean
(SD) DBP was 72 (11.9) mm Hg. Generally, mean changes
from baseline in both SBP and DBP were small at most
time points (Figure 2). There were 17 patients (4.9%)
with 21 AEs of hypertension, and 7 patients (2.0%) with
8 reported instances of increased BP. The rates of SBPs
>180 mm Hg ranged from 0.6% (month 3) to 2.3% (month
24). No patient had a DBP >120 mm Hg during the study.Heart Rate
At baseline, the mean (SD) heart rate was 71 (10.1)
beats/min. Mean changes from baseline in heart rate atmonths 12, 18, and 24 were 1 (9.8), 3 (11.5) bpm, and
0 (8.9) beats/min, respectively.
Laboratory Findings
Laboratory values showed no trends or consistent
changes from baseline that were considered to be clinically
significant. Fifty-two patients (14.9%) had a total of 158
AEs related to abnormal laboratory parameters. The most
frequently reported laboratory-related AEs were decreased
weight (3.4%), increased blood creatinine (3.1%), white
blood cells in urine (2.3%), increased blood creatine phos-
phokinase (2.0%), and increased blood urea (2.0%). Except
for one severe AE of hypoglycemia that occurred in a pa-
tient with diabetes using insulin, all AEs related to
abnormal laboratory parameters were considered mild or
moderate in severity by the investigators.
Discussion
Previous studies of the synthetic norepinephrine prodrug
droxidopa in patients with symptomatic nOH have
761S. Isaacson et al. / Journal of the American Society of Hypertension 10(10) (2016) 755–762demonstrated the drug to be effective and well tolerated in
short-term clinical trials. The present study extends our
knowledge of the safety of long-term use of droxidopa to
treat patients with symptomatic nOH secondary to auto-
nomic failure in PD, pure autonomic failure, MSA, and
NDAN. Only 7% of the study population discontinued
because of a lack of efficacy, suggesting durability of effi-
cacy of droxidopa in these patients.
There were 20 deaths over the course of this study
(5.7%), 7 of which were related to cardiovascular AEs
(carotid artery thrombosis [n ¼ 1], circulatory collapse
[n ¼ 1], myocardial infarction [n ¼ 2], cardiorespiratory ar-
rest [n ¼ 2], and cardiac arrest [n ¼ 1]). Although patients
with nOH are at increased risk of cardiovascular complica-
tions,5 the incidence of cardiovascular AEs was relatively
low (5.4%) in this study. Many patients with primary auto-
nomic failure have both orthostatic hypotension and supine
hypertension, which can be exacerbated by medications
used to treat orthostatic hypotension.13,14 In this study,
however, AEs of hypertension and increased BP, measured
in a seated or supine (ie, semirecumbent) position, were re-
ported for 4.9% and 2.0% of patients, respectively. When
compared with rates of cardiac AEs in reports of short-
term clinical trials,7–9 the risk of cardiac AEs did not
appear to increase with longer exposure to droxidopa, and
long-term droxidopa did not appear to be associated with
an increased risk of cardiac AEs in this population. Howev-
er, the enrollment criteria excluded patients with severe car-
diovascular disease, and those with cardiovascular disease
represented only a minority of patients that continued
into this long-term study. Thus, it is difficult to generalize
these safety results to patients with preexisting cardiovascu-
lar disorders. Furthermore, the study population included a
small number of patients with NDAN (n ¼ 8) and no pa-
tients with dopamine b-hydroxylase deficiency, which
limits conclusions that can be drawn about droxidopa car-
diovascular safety in patients with nOH associated with
these diagnoses.
In the current long-term droxidopa treatment study, no
new safety concerns were identified, and safety results
were similar to those observed in short-term phase 3 effi-
cacy studies.7–9 In two previous trials, AEs were reported
by 58.6% and 82.0% of patients,7,8 with lower rates
observed during the open-label dose-escalation and
double-blind treatment phases of a third trial (38.0% and
18.5%, respectively).9 Discontinuation due to an AE was
reported for 4.9% to 12.4% of patients.7–9 As expected,
overall rates of AEs and discontinuations due to AEs
were higher (75.1% and 13.4%, respectively) in the current
study given the longer duration of follow-up compared with
the short-term trials (362.6 days vs. 1–2 and 8–10 weeks).
A high discontinuation rate introduced the possibility of
retention bias and is a major limitation of this study. The
discontinuation rate may have been influenced by patients’
overall health status. Many patients in this trial had aprogressive neurodegenerative disorder that increased the
risk of developing a comorbid health condition over time.4,5
A limitation of this analysis is confounding by the open-
label nature of the study design. Although all patients
included this open-label extension study entered from
earlier double-blind, placebo-controlled trials of droxidopa,
the potential for bias associated with the open-label trial
design includes patient recruitment or retention issues
(eg, patients may be more likely to continue in an open-
label trial because receipt of active treatment is assured,
and the studies usually entail less complex treatment regi-
mens and study assessment schedules than a double-blind
study), psychological effects (from knowledge of treatment
assignment), and AEs reporting (due to patient/investigator
awareness).15,16 However, an open-label study can comple-
ment results identified in double-blind trials15 and may be
considered a relevant indicator of treatment effects consis-
tent with those that would be observed in normal clinical
practice.16
In conclusion, droxidopa was well tolerated during long-
term use in this long-term, open-label study in patients with
symptomatic nOH associated with PD, MSA, pure auto-
nomic failure, or NDAN. Most AEs, including cardiac
AEs, were mild or moderate in severity; long-term use of
droxidopa did not appear to be associated with increased
risk of cardiovascular-related AEs or increased incidence
of laboratory abnormalities.Acknowledgments
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